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Abstract
Background: Atherosclerosis is the leading cause of death in western societies and cigarette smoke is among
the factors that strongly contribute to the development of this disease. The early events in atherogenesis are
stimulated on the one hand by cytokines that chemoattract leukocytes and on the other hand by decrease in
circulating molecules that protect endothelial cells (ECs) from injury. Here we focus our studies on the effects of
"second-hand" smoke on atherogenesis.
Methods: To perform these studies, a smoking system that closely simulates exposure of humans to second-
hand smoke was developed and a mouse model system transgenic for human apoB100 was used. These mice have
moderate lipid levels that closely mimic human conditions that lead to atherosclerotic plaque formation.
Results: "Second-hand" cigarette smoke decreases plasma high density lipoprotein levels in the blood and also
decreases the ratios between high density lipoprotein and low density lipoprotein, high density lipoprotein and
triglyceride, and high density lipoprotein and total cholesterol. This change in lipid profiles causes not only more
lipid accumulation in the aorta but also lipid deposition in many of the smaller vessels of the heart and in
hepatocytes. In addition, mice exposed to smoke have increased levels of Monocyte Chemoattractant Protein–1
in circulation and in the heart/aorta tissue, have increased macrophages in the arterial walls, and have decreased
levels of adiponectin, an EC-protective protein. Also, cytokine arrays revealed that mice exposed to smoke do
not undergo the switch from the pro-inflammatory cytokine profile (that develops when the mice are initially
exposed to second-hand smoke) to the adaptive response. Furthermore, triglyceride levels increase significantly
in the liver of smoke-exposed mice.
Conclusion: Long-term exposure to "second-hand" smoke creates a state of permanent inflammation and an
imbalance in the lipid profile that leads to lipid accumulation in the liver and in the blood vessels of the heart and
aorta. The former potentially can lead to non-alcoholic fatty liver disease and the latter to heart attacks.
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Atherosclerosis is an inflammatory disease that accounts
for nearly 50% of deaths in western societies [1]. Initia-
tion of atherosclerotic plaque formation is a complex
process. It involves secretion of chemokines such as the
Monocyte Chemoattractant Protein–1 (MCP-1) [1-4] and
expression of adhesion molecules on the surface of mono-
cytes and endothelial cells [5-7]. Circulating monocytes
are recruited to sites of injured endothelial cells, adhere to
them, and migrate into the subendothelial space. Mono-
cytes in the arterial wall differentiate into activated macro-
phages that are efficient scavengers of oxidized low
density lipoprotein (LDL). When exposed to large
amounts of oxidized LDL, these macrophages accumulate
large amounts of cholesteryl esters in lipid droplets and
become "foam cells" that form "fatty streaks", the precur-
sors of more complicated atherosclerotic plaques [8,9].
Many factors can lead to initiation of atherosclerosis. In
the Framingham heart study [10-12], the best-known pro-
spective investigation that established the risk factors for
coronary heart disease and peripheral vascular disease,
smoking was identified as one of the major risk factors for
the development of atherosclerosis. Cigarette smoke is a
complex mixture of more than 4,700 chemical constitu-
ents distributed in particulate and gaseous phases, includ-
ing nicotine, aromatic hydrocarbons, sterols and
oxygenated isoprenoid compounds, aldehydes, nitriles,
cyclic ethers, and sulfur compounds [13]. Cigarette smok-
ing accelerates atherosclerosis in the coronary arteries, the
aorta, the carotid and cerebral arteries, and the large arter-
ies in the peripheral circulation. Toxic substances present
in cigarette smoke build up in the areas of curvature and
branching of arteries, injuring the endothelium [2,14].
Furthermore, epidemiological studies have shown that
both active and passive cigarette smoking increase the risk
of atherogenesis [9]. In spite of all the evidence that ciga-
rette smoke stimulates atherogenesis and lipoprotein oxi-
dation may play an important role [9], very little is known
about the biological processes induced by smoke that
contribute to increased cardiovascular disease.
Chemokines are small (8–10 kDa) stress-response pro-
teins expressed when organisms or cells are exposed to an
insult. The effects of cigarette smoke on atherosclerosis are
no exception. MSW (mainstream whole, "first-hand")
smoke and SSW (sidestream whole, major component of
"second-hand" smoke) smoke recently have been shown
to stimulate human fibroblasts to express several chemok-
ines, including MCP-1 [15-17]. This chemokine plays a
key role in atherosclerotic lesion formation [18-23]. How-
ever, studies to determine the effects of cigarette smoke on
atherosclerosis have been hampered because of the lack of
a stress-free system to expose the mice to smoke. In most
of the published studies, when the animals were exposed
to smoke, they were confined to a small device without
free access to food and water. This invariably put the ani-
mals under added stress in addition to that caused by the
cigarette smoke [24]. Therefore, for these studies we devel-
oped a smoking system that allows the animals being
exposed to cigarette smoke to move freely and consume
water and food at will. Also important, with this system
we can separate and control SSW and MSW exposure. In
addition, this system allows for control of smoke dosage.
The most commonly used mouse model systems for stud-
ies of atherogenesis are mice deficient in either apolipo-
protein E (ApoE -/-) or the low density lipoprotein
receptor (LDLR-/-). Whereas these models have the
advantage of developing lesions in a short time and are
easy to manage, lesion formation occurs under altered
physiological conditions, such as hyperlipidemia. The
LDLR-/- mice represent a genetic defect that leads to
hypercholesterolemia. These mice are excellent to model
disease conditions but do not represent well the most
common situation in humans, i.e. formation of athero-
sclerotic lesions under moderate lipidemia. Therefore, to
study the effects of SSW on biological processes involved
in initiation of plaque formation, human apoB100 trans-
genic mice [25] fed a high fat diet were used. These ani-
mals have moderate hypercholesterolemia, much like
most humans that develop atherosclerosis. Our results
show that many of the early indicators of plaque initiation
are stimulated by SSW in these mice and suggest a mech-
anism by which SSW accelerates atherogenesis.
Methods
Key reagents
All common chemicals were purchased from Sigma Bio-
chemicals and Fisher Scientific; LDL L-Type test, L-Type
HDL-C test, Colesterol C II test, and L-Type TG H test
(Waco Diagnostics, Richmond, VA); Tissue-Tek Optimal
cutting Temperature (OCT)(Sakura Finetek USA, Tor-
rance, CA); Oil-Red-O (Fisher Scientific). Primary anti-
bodies: Rabbit anti-mouse-MCP-1 (Cell Sciences, Canton,
MA); rat anti-mouse F4/80 (Serotec, Oxford, UK); rabbit
anti-human myeloperoxidase which cross-reacts with
mouse) (Biomeda, Foster City, CA); goat anti-mouse adi-
ponectin (R&D Systems Minneapolis, MN). Secondary
antibodies: chicken anti-rat-Alexa488 (Gift from Dr.
Christian Lytle); goat anti-rabbit-FITC (Zymed, South San
Francisco, CA); rabbit anti-goat conjugated to HRP (Rock-
land immunochemicals, Inc., Gilbertsville, PA); goat anti-
rabbit conjugated to HRP for subsequent use with the
Super signal West Dura extended duration substrate
(Pierce Chemical, Rockford, IL); ECL detection system
(Amersham Piscataway, NJ); Vectashield mounting
medium (Vector Laboratories, Burlingame, CA); DC pro-
tein assay kit (Bio-Rad, Hercules, CA).Page 2 of 16
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6–8 week old male mice (57BL/6Ntac-TgN(APOB100))
were purchased from Taconic Farms, Inc. [25]. 6–8 week
old male apoB100 transgenic mice (apoB100 Leu-Leu) on
57BL/6SJL background were also used. The latter mice dif-
fer from the former in that they over-express human
apoB100 without expression of apoB48, due to a muta-
tion in codon 2163 that converted CAA the codon for Gln
to CTA the codon for Leu effectively precluding the expres-
sion of apoB48 [26]. The mice were maintained in a path-
ogen-free facility with a 12-hrs light/12-hrs dark cycle and
had free access to water and food. The mice were kept on
regular diet to adapt to the environment for one week, and
then changed to a high fat diet. This diet contains 1.25%
Cholesterol, 15% cocoa butter, and 0.5% sodium cholate
[27,28] and was purchased from MP Biomedicals, Inc.
The mice were put into the smoking experiments a week
after switching them to the high fat diet. All animal exper-
iments were conducted in accordance with U.S. Public
Health Service/U.S. Department of Agriculture guidelines.
Experimental protocols were approved by the University
of California Riverside Institutional Animal Care and Use
Committee.
Exposure of the animals to smoke
The cigarettes used in this study (1R3F research grade)
were purchased from Kentucky Tobacco Research &
Development Center. A puffer box was used to generate
smoke according to FTC guidelines: 1 puff/minute, 3 sec-
onds/puff. Each smoke type was mixed with fresh air
before it was puffed through a tube into the small mouse
exposure chambers (Teague Enterprise). The air in the
chambers was exhausted using a fan (vortex blower). The
mice in the smoking groups were exposed to the smoke
for 6 hrs/day (10 min smoking with 5 min break), 5 days/
week. Smoke particle concentration in the chamber was
maintained at 25 ± 2 mg/m3 by adjusting the fresh air
entering and exhausting from the chamber. Smoke sam-
ples taken from each chamber were passed through a fil-
ter; the particulate material deposited on the filter was
measured by weighing the filter before and after smoke fil-
tration. The vacuum pump gas meter recorded the smoke
sample volume passed through the filter. Total particulate
matter (TPM) was calculated by dividing the total particle
weight trapped on the filter by the volume passed through
the filter.
Smoke exposure analysis
Inhalation of smoke by the mice was monitored by meas-
uring the blood carboxyhemoglobin level according to
Griffith et al. [24]. Briefly, 20 μl of blood from the mouse
was diluted to 20 ml with 0.04% ammonium hydroxide.
The absorbance values at 413 nm and 420 nm were deter-
mined and the 420/413 ratio was calculated. An increase
in this ratio reflects smoke exposure. We also measured
and calculated the blood carboxyhemoglobin level.
Briefly, 10 μl of blood were mixed with freshly prepared
sodium dithionite (2 mg/ml) in 0.01 mol/l TRIS
(hydroxymethyl) aminomethane solution, and absorp-
tion spectra at 420 and 432 nm were recorded within 2–3
minutes. The concentration of COHb was calculated
using the following equation: Percent COHb = 100 × [1 -
(Ar × F1)]/[Ar × (F2 - F1) - F3 + 1], where Ar = Abs420 nm/
Abs432 nm, F1 = 1.3007, F2 = 0.4648, F3 = 2.0526
according to previously published work [29,30].
Plasma lipid analysis
Levels of total cholesterol (TC), triglycerides (TG), low
density lipoproteins (LDL), and high density lipoproteins
(HDL) in plasma were determined by enzymatic assay
using commercially available kits (Wako Chemical Co.)
and following the instructions given by the company.
Tissue lipid analysis
After the mouse was sacrificed, its liver was harvested and
frozen immediately on dry ice and kept at -72°C. Lipids
were extracted from about 300 mg liver tissue (wet
weight) into 30 ml chloroform: methanol (2:1) according
to the method of Folch et al. [31]. Phases were separated
by addition of 6 ml 0.05% H2SO4 and aliquots of
extracted lipids were mixed with 1% Triton X-100, dried
under a stream of N2, and re-dissolved in water [32].
Commercial kits were used for the specific determination
of total cholesterol and triglycerides (WAKO Chemicals
USA, Inc., Richmond, VA). The hepatic lipid concentra-
tions were expressed as milligrams of lipids per gram of
wet weight.
Lesion analysis
Mice were fasted for 4 hrs, anesthetized with ketamine
and xylazine and were perfused with 10–15 mL of PBS,
pH 7.4 (80 mmHg), followed by 4% paraformaldehyde
for 3–5 minutes [21]. The heart and aorta were removed
and fixed for an additional 1–2 hrs in 4% paraformalde-
hyde followed by infiltration with 30% gum sucrose (1%
gum Arabic, 30% sucrose in PBS) for 24 hrs at 4°C and
embedded in OCT for sectioning [33]. Briefly, the OCT-
embedded, frozen aortas were cross-sectioned serially at
10-μm thicknesses for a total of 300 μm beginning at the
base of the aortic valve, where all three leaflets are first vis-
ible. Every fourth section for a total of five sections from
each animal was stained with Oil-Red O (Fisher scientific
company) and counterstained with hematoxylin (Sigma)
to identify the lipid-rich lesions. Average lesion sizes of
these 5 cross sections were used for morphometric evalu-
ations. Images were captured using a Nikon microscope
with camera and scanned into a computer. Quantitation
of atherosclerotic lesions was performed using NIH Image
software. Results are expressed as percent of the total
cross-sectional vessel wall area [21].Page 3 of 16
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Sections of the heart and aorta were used for immunos-
taining for MCP-1 with a primary rabbit anti-mouse poly-
clonal antibody (Cell Sciences). As secondary antibody, a
FITC-labeled goat anti-rabbit IgG was used. For macro-
phage staining, rat anti-mouse F4/80 antibody (Serotec,
undiluted) was used as primary antibody and Alexa Fluor
488-labeled chicken anti-rat antibody was used as second-
ary antibody. For neutrophil staining, rabbit anti-MPO
antibody was used as primary antibody and FITC-labeled
goat anti-rabbit IgG was used as secondary antibody. For
splenic cell staining, rat anti mouse CD4+, IL-4, or IFNγ
antibodies (BioLegend) were used as primary antibodies
and FITC-labeled goat anti-rat IgG was used as secondary
antibody. Quantitation was performed by counting the
labeled cells in 3 high-power fields/section of spleen, tak-
ing the average and then calculating the ratio. In cell clus-
ters, the number of stained cells was estimated by the size
of the cells.
Cytokine antibody array
Cytokine levels in the plasma were measured using Q-
Plex™ Mouse Cytokine array (Quansys Biosciences, Utah,
USA), which is a fully quantitative ELISA-based test in
which each well of a 96 well plate was coated with 16 dis-
tinct capture antibodies in a defined array. 30 μl of
cytokine standard or plasma sample were added into the
appropriate wells. After 1 hr incubation, the wells were
washed 3 times and probed with streptavidin-HRP for 15
minutes at room temperature. After washing 3 times and
adding the substrate, the images were captured by a
cooled CCD camera (MicroMAX-1300B, Roper Scientific)
and analyzed using the Quansys image analysis software.
The concentrations of cytokine were calculated and plot-
ted using the standard curve.
Results
Cigarette smoking system and calibration
A system that can be used to administer cigarette smoke to
small animals under conditions that minimize stress was
developed (Figure 1A). In this system, the MSW (Main-
stream whole, "first-hand") and the SSW (Sidestream
whole, a major component of "second-hand") smoke
generated from a puffer box are distributed to separate
smoking chambers. MSW smoke is defined as the smoke
inhaled by the smoker, whereas SSW smoke is defined as
the smoke emanating from the burning end of the ciga-
rette. For this study, the mouse cages with food and water
are introduced into the chamber that receives only SSW;
the mice are free to move around and eat and drink at will.
Therefore, the mice are exposed only to SSW, the major
component of second hand smoke. The dose of smoke in
each chamber is controlled by adjusting the intake and
exhaust valves (see Materials and Methods). When mak-
ing the measurements, the filter unit connected to the vac-
uum pump gas meter is connected to the smoking
chamber, and the smoke sample from the chamber passes
through the filter unit. The filter unit holds a special filter
paper that can trap particles in the smoke sample. The vac-
uum pump meter was set to collect sample for 10 min-
utes, and the volume of the smoke passed through the
filter unit can be calculated from the meter readings of the
start and end points. The weight of the filter was deter-
mined both before and after each sampling; the weight
difference of the filter paper is the weight of particulate
matter trapped by the filter. The smoking dose was
obtained by calculating the weight of particulate matter
per cubic meter of sample in the chamber.
Because second-hand smoke exposure occurs in environ-
ments that are usually out of control of the person(s)
being exposed, e.g. children and teens of households in
which the parents smoke, we decided to focus our studies
on the effects of SSW on processes that relate to athero-
genesis. As in previous studies [34,35], a smoking dose of
25 ± 2 mg/m3 total particulate matter (TPM) was used.
The mice were exposed to SSW for 6 hours, with 5 minutes
break every 10 minutes, the time taken to smoke 1 ciga-
rette. The total exposure thus is 24 cigarettes/day, which is
similar to the average number of cigarettes smoked
indoors in a typical smoker's home (an average smoker
smokes about 1.4 packs or 28 cigarettes/day [36]). To
arrive at the dose of 25 ± 2 mg/m3, the chambers were set
at a pressure of 0.42 inches w.c. (water column), which
equals 0.104 kPa. For the smoking cage used (19 in × 19
in × 16 in), the flow rate at this pressure was 28.1 liter/
min. Extra smoke was filtered to reduce air pollution and
expelled from the chamber into the fume hood by the
blower fan (Figure 1B). To verify that the mice were
exposed to cigarette smoke, the blood carboxyhemo-
globin (CoHb) level was measured. SSW-exposed animals
showed an increased level of blood carboxyhemoglobin,
as expected (Figure 1C). COHb levels were significantly
higher in mice exposed to CS compared to mice exposed
to air (8.11 ± 1.08%, n = 4 versus 2.38 ± 0.16%, n = 6,
respectively; P < 0.01). The mean COHb concentrations
for nonsmokers were reported to be about 1–2% and
those for smokers about 4–7% [37,38]. In heavy smokers,
the COHb concentration was 12%. In the mice model, the
value may be slightly higher, 1.2 ± 0.8% versus 12.2 ±
4.9%, respectively [37]. Therefore, the amount of pulmo-
nary stress to the animals was similar to reported studies.
SSW causes changes in lipid physiology
In patients with cardiovascular disease, the HDL/LDL
ratio decreases significantly. A low HDL/LDL cholesterol
ratio is an important risk factor for atherosclerosis. HDL
participates in reverse cholesterol transport, i.e., it carries
cholesterol away from the arteries and other peripheral
tissues and back to the liver for excretion from the body.Page 4 of 16
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Schematic representation of the Smoking System, smoking dose calibration, and effects of cigarette smoke on blood carboxy-hemoglobin (CoHb) levelsFigure 1
Schematic representation of the Smoking System, smoking dose calibration, and effects of cigarette smoke on 
blood carboxyhemoglobin (CoHb) levels. (A) Schematic representation of the smoking system. Smoke was generated by 
using a puffer box built by the University of Kentucky [33] and chambers built by Teague Enterprises. Each smoke type can be 
mixed with fresh air before it was puffed through a tube into the exposure chambers. In this study only the SSW chamber was 
used. The air and smoke in the chamber were exhausted using a blower fan (air moving fan). A vacuum pump/gas meter was 
used for dose calibration only. (B) The smoking dose was calibrated to 25 mg TPM/m3 by adjusting the intake and exhaust 
valves. Smoke samples taken from the SSW chamber were passed through a filter unit; the particulate material deposited onto 
the filter was measured by weighing the filter before and after smoke filtration. The vacuum pump gas meter recorded the 
smoke sample volume passed through the filter. Total particulate matter (TPM) was calculated by dividing the total particle 
weight trapped on the filter by the volume passed through the filter. w.c. = water column. (C) Mice were exposed to SSW 
smoke for 6 hrs intermittently and blood was drawn to test for carboxyhemoglobin. Blood was treated with ammonium 
hydroxide, absorbance measured at 420 nm and 413 nm and the ratio plotted. C = control.
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1This removes excess cholesterol from plaques, thus mini-
mizing the buildup of cholesterol in the artery walls. SSW
smoke decreases the HDL level in the plasma (Figure 2A)
and decreases the ratio between HDL and LDL, HDL and
triglyceride (TG), and HDL and total cholesterol (TC)
(Figure 2B–D). The total plasma cholesterol level is
342.35 ± 29.59 mg/dl for control mice, and 334.72 ±
22.37 mg/dl for SSW-exposed mice, respectively.
To determine if the changes in the lipid levels induced by
SSW lead to an adverse effect in the hApoB100 transgenic
mice (57BL/6Ntac-tgN) [25], Oil-Red-O staining of cross
sections of the heart/aorta tissues were performed. SSW-
exposed animals did not only accumulate more lipids in
the aortic walls (Figure 3A–D), but also had many of the
smaller vessels in the heart tissue itself that were almost
filled with lipid (Figure 3E, F). The lesion areas measured
in the cross sections of the aorta account for 23.83 ±
3.41% and 49.05 ± 3.67% of the total aorta wall areas for
control mice and SSW exposed mice, respectively (Figure
3G). To confirm these results, transgenic mice expressing
only human apoB100 were used. These latter mice more
closely mimic human conditions because they produce
human apoB100 that is a constituent of the atherogenic
LDL, but not apoB48, a major cholesterol carrier in mice
that is normally not considered to associate with athero-
genic lipoproteins[26]. The same effects were found: more
lipids accumulated in the aortic wall and in the small ves-
sels of the heart after cigarette smoke exposure (data not
shown).
The amount of total cholesterol and triglycerides in liver
tissue were measured because synthesis and metabolism
of lipids occur in the liver. Although there was no signifi-
cant change in the total cholesterol level (Figure 4A), the
triglyceride levels increased significantly after the mice
were exposed to SSW (Figure 4B). Oil-Red-O staining of
liver sections showed that there was much more lipid
accumulation in the liver of mice exposed to SSW (Figure
4D) than in the liver of control mice (Figure 4C). Diff-
Quick staining shows that the lipid droplets are much big-
ger in the SSW smoking mice than in the control mice
(Figure 4E &4F).
Mice exposed to SSW have increased levels of MCP-1 in 
both plasma and heart/aortic tissues
MCP-1 has been shown to be a critical participant in
atherogenesis because it is a potent chemoattactant for
monocytes that infiltrate the intimal layer of arterial walls
following injury [1,2,4]. Thus, the levels of MCP-1 in the
plasma of SSW-exposed mice were examined and were
found that early in the process of smoking the mice have
normal MCP-1 levels but by the end of one year of smok-
ing there is a significant increase in the levels of circulating
MCP-1 (Figure 5A). The heart/aorta tissues were also
Effect of cigarette smoke on the HDL and its ratio to other plasma lipidsFigure 2
Effect of cigarette smoke on the HDL and its ratio to 
other plasma lipids. Mice were exposed to SSW 6 hrs/day 
intermittently, 5 days a week. Blood samples were collected 
from the tail vein and, after centrifugation, the plasma was 
used to analyze for levels of HDL and other lipids by enzy-
matic reaction using colorimetric methods with commercially 
available kits (Wako Chemicals). After incubating with color-
ing reagent that only reacts with a specific cholesterol or 
type of lipid, the absorbance was measured and the concen-
tration of each was calculated by plotting the measured val-
ues against a standard curve. (A) The levels of HDL in the 
blood of mice exposed to SSW are significantly lower than in 
the non-exposed mice. The ratios of HDL to LDL (B), HDL 
to TG (C), and HDL to TC (D) are all significantly lower in 
the SSW exposed mice.
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Lipid accumulation in arterial blood vesselsFigure 3
Lipid accumulation in arterial blood vessels. Oil red O was used to detect the presence of lipids in tissue sections of the 
heart and aorta. (A) & (B) Presence of higher lipid deposition in the root of the aorta in the smoke-exposed mice. (C) & (D) 
Similar to A&B but in the proximal part of ascending aorta. (E) & (F) Small blood vessels in the heart muscle of SSW- exposed 
mice show much more lipid accumulation than in control mice. Thin black lines outline the outside of the vessel walls. (G) The 
lesion area in both control and SSW-exposed mice was measured as described in the Materials and Methods. The results are 
expressed as percentage of total area of aorta wall in cross section. Data are mean ± SEM for each group. Statistical analyses 
were done according to unpaired t test. *P < 0.05 vs. control. The mice were exposed to SSW for 1 year. The images are rep-
resentative of 2 mice per group.
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Lipid accumulation in liver tissueFigure 4
Lipid accumulation in liver tissue. About equal amounts of snap-frozen liver from the sacrificed mice of both control and 
SSW mice were used for lipid extraction with chloroform: methanol (2:1). The extracted lipids were dried and redissolved in 
1% Triton X-100. Commercial kits (WAKO Chemicals USA, Inc., Richmond, VA) were used for determination of (A) total 
cholesterol and (B) triglycerides. (C-F) Oil Red O staining of frozen liver sections reveals the lipid contents in the liver of con-
trol mice (C) and SSW mice (D). The liver of control mice (E) and SSW mice (F) were also stained with Diff-Quick to show 
their histological structure. The mice were exposed to SSW for 1 year. Representative images of one mouse out of three.
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1examined for the level of MCP-1 protein by immunoblot
analysis. These tissues were found to contain higher levels
of the chemokine (Figure 5B); immunolabeling showed
MCP-1 is primarily localized in the endothelial cells of
large vessels (Figure 5C; arrowheads). Some staining was
also present in cells of the adventitia (Figure 5C; arrows).
These results in apoB100 mice were independent of
apoB48 expression.
Presence of macrophages in the arterial walls of SSW-
exposed mice
The process of atherogenesis is characterized by monocyte
migration from the lumen to the intimal (subendothelial)
layer of the blood vessel wall and there, in the presence of
cytokines, differentiate into macrophages. These macro-
phages then take up oxidized LDL, which results in
cholesteryl ester accumulation and "foam cell" formation,
leading to early plaque formation. To determine the effect
of SSW on these cell types in the heart blood vessels, tissue
sections from the control and SSW exposed mice were
immunolabeled with antibodies to F4/80, a marker for
macrophages. Many more macrophages were present in
the mice exposed to SSW smoke than in those breathing
fresh air (Figure 6A, B). On the other hand, probing for
neutrophils using antibodies to myeloperoxidase showed
that these leukocytes are not present in the arterial vessel
walls even in the mice exposed to SSW (Figure 6C, D),
hence the effects of SSW are very specific for macrophages.
These results support previous studies that showed that
neutrophils were not implicated in atherosclerotic lesion
development.
Changes in adiponectin and TNFα levels in the plasma of 
SSW-exposed mice
Adiponectin is a protein primarily secreted by adipocytes
that has potential anti-atherogenic properties [39-41]. The
possibility that SSW exposure results in a decrease in the
levels of circulating adiponectin was examined. Using
immunoblot analysis and reducing conditions, it was
found that the mice exposed to SSW had decreased
plasma levels of adiponectin monomer (Figure 7A).
Production of MCP-1 and adiponectin are stimulated by
TNFα [42-44]. At 14 weeks of smoking, there were no sig-
nificant changes in the TNFα levels caused by exposure to
SSW smoke. However, after 1 year of smoking, plasma
TNFα levels were significantly increased compared to the
control mice (Figure 7B).
Changes in cytokine profiles in the plasma of SSW-
exposed mice
T-cell activation is an ongoing process in atherosclerotic
lesions [45]. These immune cells can become activated
and produce pro-inflammatory and cell-mediated
responses (Th1 type), or produce cytokines that activate
MCP-1 in the plasma and heart/aortic tissues in human apoB100 transgenic mice on high fat diet and exposed to SSW: (A) Levels of MCP-1 in the plasma of moking mice at tw  different time points durin  smok ngFigure 5
MCP-1 in the plasma and heart/aortic tissues in 
human apoB100 transgenic mice on high fat diet and 
exposed to SSW: (A) Levels of MCP-1 in the plasma of 
smoking mice at two different time points during smoking. 30 
μl of cytokine standard or plasma sample were added into 
the appropriate wells of a Mouse Cytokine array (Quansys 
Biosciences, Utah, USA) containing an antibody to this chem-
okine. The images were captured by a CCD camera and ana-
lyzed using the Quansys image analysis software. The 
concentration of MCP-1 was calculated and plotted using a 
standard curve. (B) Immunoblot analysis for MCP-1 in the 
heart/aortic tissue (the upper half of the heart together with 
ascending aorta). The protein extractions were quantified 
using a DC protein assay kit (Bio-Rad, Hercules, CA) and 
equal amounts of protein were loaded in each lane of SDS-
Polyacrylamide Gel. A 45 KD protein was used to evaluate 
equal loadings because this protein is always constant, inde-
pendent of the treatment when the gels are stained with 
Commasie blue. (C): Immunolabeling for MCP-1 in an arte-
rial vessel of the heart tissue shows that this chemokine is 
produced by the endothelial cells (arrowheads) and by some 
of the cells in the adventitia (arrow). The mice were exposed 
to SSW periodically for 1 year. Representative images of one 
mouse out of three.
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1antibody-producing cells (Th2 type). Using a cytokine
antibody array containing antibodies to detect Th1 and
Th2 responses, we measured cytokine levels in the plasma
of mice exposed to SSW. Cytokines such as IL-12 that pro-
mote Th1 responses and others such as IL-4 that promote
Th2 responses were detected. It was found that at 14
weeks of SSW smoking, the plasma levels of the pro-
inflammatory Th1-inducing IL-12 cytokine was signifi-
cantly increased (Figure 8A) whereas IL-4, that promotes
Th2 responses and antibody production, was significantly
lower in the mice exposed to SSW smoke (Figure 8B).
However, at 1 year of exposure to SSW, whereas the levels
of IL-12 decreased slightly (Figure 8A), the levels of IL-4
remained sharply decreased (Figure 8B). Another critical
cytokine required for Th1 immunity, IFNγ, also signifi-
cantly increased at 1 year of exposure to SSW (Figure 8C).
To further explore the possibility that Th1 cytokines
remain elevated in the blood of smokers, we immunola-
beled sections of spleen with antibodies to CD4, IL-4, and
IFNγ γ and counted the number of cells that were positive
for CD4, IL-4, and IFNγ. The results showed that the ratio
of IFNγ to IL-4 was 2.82:1 in mice exposed to SSW, com-
pared to 1.20:1 in control mice (Fig 9 and table 1). These
results taken together suggest that smokers are in a pro-
inflammatory state. That is, the normal switch from Th1
to Th2 response during immune system activation upon
Macrophages and neutrophils in apoB100 transgenic mice on high fat diet: (A) & (B) Tissue sections of arterial blood vessels in the heart were immunolabe ed with the antibody to F4/80 which is specific to macrophag s, and (C) & (D) with an antibody tomyel eroxid se to detect neutrophilsFigure 6
Macrophages and neutrophils in apoB100 transgenic mice on high fat diet: (A) & (B) Tissue sections of arterial 
blood vessels in the heart were immunolabeled with the antibody to F4/80 which is specific to macrophages, and (C) & (D) 
with an antibody to myeloperoxidase to detect neutrophils. Macrophages were observed in the walls of arterial vessels in mice 
exposed to SSW smoke but not in the control mice. However, neutrophils were not found in the arterial vessel walls of either 
control mice or mice exposed to SSW. The mice were exposed to SSW for 1 year as described in the Materials and Methods. 
Representative images of one mouse out of three.
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1an insult, in this case circulating cigarette smoke compo-
nents, does not occur.
Discussion
It is well known that cigarette smoking is detrimental to
human health, leading to cardiovascular disease and can-
cer. Although cigarette smoke is widely accepted as an
environmental factor that aggravates atherosclerosis
[1,10-12], less well known are the biological processes by
which cigarette smoke stimulates atherogenesis. By using
a smoking system that greatly decreases the stress exerted
Plasma levels of adiponectin and TNFαFigure 7
Plasma levels of adiponectin and TNFα. (A) Immunob-
lot analysis shows the levels of adiponectin in the plasma. 
Blood sample from both control and SSW smoking mice 
were applied to 7.5% polyacrylamide electrophoresis gel and 
transferred to the nitrocellulose membrane. Adiponectin was 
probed with a goat anti-mouse adiponectin antibody and with 
a secondary conjugated to HRP for subsequent use with the 
enhanced chemiluminescence system (ECL, Amersham Phar-
macia). Less adiponectin was detected in the plasma of mice 
exposed to SSW. Samples representative of 2 animals per 
group. (B) Cytokine array results showing TNFα levels in the 
plasma. At early stages of smoking, there was no significant 
difference between the TNFα levels in the control and SSW 
smoked mice, whereas at late stages of SSW smoking, the 
TNFα level in plasma was significantly increased. This incre-
ment was correlated with the decrease of adiponectin and 
increment of MCP-1 in the plasma. Samples were done in 
triplicate.
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Plasma levels of specific cytokines related to the immune respons  in atheros lerosisFigure 8
Plasma levels of specific cytokines related to the 
immune response in atherosclerosis. Cytokine array 
results show the changes of the cytokines IL-12 (A), IL-4 (B), 
and IFNγ (C) in the plasma of hApoB100 transgenic mice that 
were exposed to SSW smoke. The cytokines in the plasma 
were captured by antibodies coated on the bottom of 96-
well plates (Quansys Biosciences, Utah, USA). After washing, 
probing with streptavidin-HRP, and reacting with substrate, 
the images were captured with CCD camera (Roper Micro-
max 1300B). The strength of signal was translated into con-
centration of cytokine by plotting against a standard curve.
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1on the animals, the effects of SSW smoke can be more
accurately decoupled from effects of stress. Here we have
shown that: (i) SSW smoke decreases circulating HDL and
alters the physiology of other lipids, resulting in a signifi-
cant increase in the area of the lesions found in the aorta
and in more lipid deposition in the blood vessels of the
heart; (ii) mice exposed to SSW have increased levels of
MCP-1; (iii) macrophages accumulate in the arterial walls
of mice exposed to cigarette smoke; (iv) adiponectin lev-
els are decreased in the plasma of SSW smoking mice; (v)
SSW smoke exposure favors a Th1 immune response in human apoB100 Transgenic miceFigure 9
SSW smoke exposure favors a Th1 immune response in human apoB100 Transgenic mice. Tissue sections of the 
spleen were labeled with rat anti-mouse CD4+, IL-4, and IFNγ antibodies, and detected by FITC-labeled goat anti-rat IgG. (A-
F) Immunolabeling showing the peripheral lymphocytes in spleen expressing CD4+ (A, B), IL-4 (C, D), and IFNγ (E, F) in 
hApoB100 transgenic mice that were exposed to normal air (A, C, E) or SSW smoke (B, D, F).
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1cigarette smoke stimulates accumulation of lipids in liver
cells; and (vi) SSW stimulates cytokines that enhance the
Th1 response (e.g. IL-12 and IFNγ) and suppresses
cytokines that stimulate the Th2 response (e.g.IL-4).
Most humans suffering from atherosclerosis only have a
moderately elevated cholesterol level, and have normal
LDL receptors; hence the apoB100 transgenic mice used in
this study may be a more physiologically relevant model
for the study of atherosclerosis in most humans than
other genetically modified mice. ApoB100 mice develop
atherogenesis only on a relatively high fat diet, have mod-
erately elevated cholesterol levels and have elevated levels
of the apoB100 protein in their blood [22]. In general,
humans that develop atherosclerosis have all three condi-
tions; in particular they have elevated apoB100 [46-48]
and consume high fat foods. All these features make
human apoB100 transgenic mice the murine model of
choice to study the "common" atherosclerotic disease
state in humans exposed to cigarette smoke. As shown
here, cigarette smoke increases lipid accumulation in
blood vessels and induces more macrophage accumula-
tion in the subendothelial layers of the aorta. These results
correlate well with previous reports in which hyperlipi-
demic children were found to have low serum HDL levels
when exposed to second-hand smoke [49]. The accumula-
tion of macrophages in blood vessel walls and the pres-
ence of lipids are key steps in atherosclerotic plaque
initiation.
Because MCP-1 functions in attracting monocytes, which
migrate through the endothelial layer, differentiate into
macrophages in the arterial walls and become activated
and ingest oxidized lipids, it is quite possible that this
molecule is a key modulator in the process of initiation of
atherosclerosis plaque formation. For example, MCP-1
production is stimulated by balloon injury in rabbits [19]
and pigs [20] and this stimulation is correlated with an
increase in the number of monocytes and macrophages in
the arterial wall. Furthermore, studies in apoE-/- mice
show that these mice over-express MCP-1 and have accel-
erated atherosclerosis [21]. In contrast, knockout of either
MCP-1 [22] or the MCP-1 receptor, CCR2, resulted in a
marked reduction in atherosclerotic plaque formation
[23]. Our data show that in mice exposed to SSW, the
endothelial layer of arterial blood vessels produces higher
levels of MCP-1, showing that this chemokine is in the
right place at the right time to contribute to the initiation
of plaque formation. Studies are under way to determine
whether the MCP-1 increase is required for SSW-induced
atherogenesis.
Artherosclerotic plaque formation may also be related to
adipose tissue secreted molecules such as adiponectin.
This is a 247 amino acid bioactive protein secreted by adi-
pocytes [39]. Although adiponectin is an important mod-
ulator of glucose and lipid metabolism, recent studies
found that adiponectin is potentially anti-atherogenic and
anti-inflammatory [40,41]. In apo-E -/- mice, atheroscle-
rotic plaque size decreased when adiponectin was over-
expressed [50,51]. In patients with cardiovascular disease,
plasma concentrations of adiponectin decreased in smok-
ers [52,53]. Our data suggests that adiponectin is another
modulator of cigarette-smoke-induced plaque formation.
The low concentration of adiponectin in the blood of
SSW-exposed mice shows that cigarette smoke can affect
the levels of this protein in circulation. We are in the proc-
ess of obtaining transgenic mice expressing both apoB100
and adiponectin to determine whether excess of this latter
protein can decrease cigarette-smoke-induced atherogene-
sis.
MCP-1 is expressed by many different cell types upon
stimulation of the cells by stress-inducing agents whereas
adiponectin is constitutively expressed by adipocytes and
is found at high concentrations (2–10 μg/ml) in the
blood. Is the inverse expression level of MCP-1 and adi-
ponectin important in SSW-induced atherosclerotic
Table 1: Number of splenic cells/HPF that express CD4+, IL-4 and IFNγ
Cell numbera
Treatment CD4+ IL-4 IFNγ IFNγ/IL-4
Control 20.67 ± 4.49
(n = 3)*
27.00 ± 2.31
(n = 3)**
32.23 ± 2.33
(n = 3)
1.20
SSW 112.00 ± 4.62
(n = 3)$, #, £
33.33 ± 6.69
(n = 3)§, †
94.00 ± 7.81
(n = 3)‡
2.82
a, Splenic lymphocyte numbers were determined by immunolabeling of spleen sections with anti-CD4. The cell numbers in the clustered staining 
area was estimated by the size of the cells. P > 0.05 is considered not significant change, and p < 0.001 is considered very significant change. n 
represents the number of different high power fields within a tissue section.
*, Control/CD4+ vs. control/IL-4, and control/CD4+ vs. control/IFNγ: p > 0.05; **, control/IL-4 vs. control/IFNγ: p > 0.05, $, SSW CD4+ vs SSW 
IL-4: p < 0.001, and #, SSW CD4+ vs SSW/IFNγ: p > 0.05; § SSW IL-4 vs. SSW/IFNγ: p < 0.001 £, SSW CD4+ vs contol/CD4+: p < 0.001; †, SSW 
IL-4 vs. control/IL-4: p > 0.05; ‡, SSW/IFNγ vs control/IFNγ: p < 0.001 HPF = High Power FieldPage 13 of 16
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BMC Cardiovascular Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2261/7/1plaque formation? This connection may be critical for
plaque formation and could be dependent on the cell-
mediated immune responses to cigarette smoke compo-
nents. As an important inflammatory cytokine, TNFα can
upregulate MCP-1 expression [53] and down-regulate adi-
ponectin expression [44]. In SSW-exposed mice, the MCP-
1 levels at 14 weeks of smoking correlate well with the lev-
els of TNFα at this same time. Furthermore, after 1 year of
SSW exposure, when the levels of TNFα are significantly
increased, the MCP-1 levels are also significantly
increased whereas adiponectin levels are significantly
decreased. Therefore, on the one hand, cigarette smoke
increased the levels of TNFα thereby causing MCP-1
expression by the endothelial cells of the aorta to attract
monocytes, which led to accumulation of oxidized lipids
in the subendothelial layer. However, on the other hand,
increased levels of TNFα induced by cigarette smoke also
decreased the circulating levels of adiponectin, which lim-
ited its function in protecting the endothelial layer. These
two processes thus may both contribute to enhancing the
progression of the initiation of atherosclerotic plaque for-
mation.
T-cells are known to be present in atherosclerotic lesions,
suggesting that they are important in cell-mediated
immune responses during atherogenesis. Most of these T
cells are CD 4+ T cells (Th type). The pro-inflammatory
cytokine IL-12, the center for Th1 immunity [54], stimu-
lates Th1 cell differentiation and expression of other
cytokines, such as TNFα and IFNγ [55]. IL-12 levels were
significantly increased at the early stage of SSW exposure,
and this correlated well with the significant increase in the
levels of TNFα over time. There was no significant change
in the level of IL-12 for the mice exposed to SSW, meaning
that these mice are constantly stimulated to produce this
cytokine by SSW components. These data show that SSW
can stimulate IL-12 and IFNγ expression and thus enhance
the Th1 response in atherogenic lesion formation. On the
other hand, SSW also suppress the expression IL-4, a Th2
stimulating cytokine indicating that the switch from a
pro-inflammatory Th1 response to an antibody-depend-
ent Th2 response is impaired.
In addition to all of these effects, cigarette smoke also
causes hepatic steatosis (fatty liver), which in clinical stud-
ies correlates with atherogenesis. Although there are no
direct studies regarding the relationship between cigarette
smoking and hepatic steatosis, it has been reported that
cigarette smoking can increase severity of hepatic lesions
in patients with chronic hepatitis C [56,57]. Starting
smoking was also associated with deterioration of serum
alanine aminotransferase (ALT) in NAFLD patients [58].
One potential complication in interpreting our results on
cigarette smoke-induced steatosis is that apoB100 trans-
genic mice require high fat diet to induce lesion develop-
ment in the aorta in a reasonable time frame. The high fat
diet contains cholate, which is known to cause liver dys-
function and inflammation. However, we believe that our
results show true effects of cigarette smoke because,
although the control groups were not exposed to SSW,
they were fed the same diet as the mice that were exposed
to SSW. Therefore, the difference in lipid metabolism can
be attributed to the effect of cigarette smoke. However, the
possibility remains that some of the effects are due to an
interaction between smoke exposure and dietary cholate.
Conclusion
Our results suggest that the levels of both MCP-1 and adi-
ponectin are regulated by the cytokine TNFα, which is
modulated by IL-12. Because modulation of both MCP-1
and adiponectin plays important functions in atheroscle-
rosis, the imbalance of these two molecules may be key to
atherogenesis. Our results also suggest that SSW inhibits
the switch of Th1 to Th2 response, leading to an imbal-
ance of the Th response, thereby linking the importance of
the immune response to the process of second-hand
smoke-induced atherogenesis and suggesting that smok-
ers may live in a permanent state of inflammation.
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